[ad_1]
94.1% prevention rate as a result of phase 3 clinical trials …
Modena announces the results of the phase 3 clinical trials of the COVID-19 vaccine and enters an emergency use procedure through the US health authorities.
On the 30th of last month (local time), the American biological company Modena Therapeutics announced the final results of phase 3 clinical trials of ‘mRNA-1273’, a corona19 mRNA vaccine candidate, which is being developed internally. It said it will apply for conditional approval for use in European Medicines (EMA).
According to Modena, the final analysis of the phase 3 clinical trial of the vaccine showed a preventive effect of 94.1%. This is about the same figure as 94.5% from last month’s preliminary analysis. In particular, he highlighted that the prevention rate for severe Corona 19 is 100%.
Moderna cooperated with the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) and the Agency for Advanced Biomedical Research and Development (BARDA) of the US Department of Health. These results were obtained using the conducting a clinical trial.
Modena expects the rush-use approval review of the vaccine to take place in the FDA Advisory Committee on the 17th, and when approval for use is decided, the actual supply will take place where the supply is scheduled. Major foreign media in the United States estimate that production of 20 million doses of Modena’s vaccine will be possible in the United States.
Before that, on the 20th, a candidate vaccine developed by Pfizer, a global pharmaceutical company in the United States, also applied for an emergency use approval from the FDA, saying it showed a 95% prevention rate in clinical trials. phase 3, and which is being reviewed by the FDA advisory committee on day 11.
Modena said that not only the FDA and the EMA, but also health authorities such as Canada, Switzerland, the United Kingdom, Israel and Singapore have started the review process and will submit an expedited registration and preliminary screening request to the World Organization of the Health (WHO).
Stephen Bansel, CEO of Modena Therapeutics, said: “In this positive primary analysis, it showed a prevention effect of 94.1% and, more importantly, it was confirmed that the prevention effect of severe Corona 19 was confirmed. We believe that it will be a powerful new alternative to induce children and help prevent serious illness, hospitalization and death ”.
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited
